ClinicalTrials.gg
CompletedNCT01560624FREEDOM-EVUpdated Feb 13, 2020Results posted

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

A Phase 3 interventional study of Treprostinil Diolamine and Placebo in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 155 sites in 23 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-02-13.

Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
690
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
2nd of 44
690 · median 32
Started
2012
with 4 others
Phase 3
14 of 44
1 open now
Registered
21st of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 2nd largest by enrollment, is one of 5 that started in 2012, is one of 14 in phase 3, and was the 21st registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 141 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension.

Read the detailed description

Study TDE-PH-310 is an international, multicenter, randomized (1:1 oral treprostinil (UT-15C): placebo), double-blind, placebo-controlled study in subjects with pulmonary arterial hypertension (PAH) who are receiving background oral monotherapy for PAH for at least 30 days at randomization. Subjects are randomly allocated to receive oral treprostinil extended-release tablets or placebo by a stratified randomization by type of background therapy (Strata 1: phosphodiesterase type 5 inhibitor [PDE5-I] or soluble guanylate cyclase [sGC] stimulator; Strata 2: endothelin receptor antagonist [ERA]. Subjects are also stratified by baseline 6-minute walk distance (6MWD) less than or equal to 350 m or greater than 350 m. Subjects receive their first dose of study drug (0.125 mg) or matching placebo on the day of randomization. Oral dosing of study drug is continued at 0.125 mg 3 times daily (TID; every 6 to 8 hours) with food. The dose (or matching placebo) is titrated throughout the study up to a maximum dose of 12 mg TID to reach and maintain a tolerated dosing regimen that provided optimal clinical benefit. Once randomized, subjects return for study visits every 4 weeks for the first 12 weeks, then every 12 weeks for the duration of the study. Subjects continue in the study until experiencing clinical worsening, the number of adjudicated events necessary for study closure occurr, or prematurely discontinue participation in the study for any reason other than protocol-specified clinical worsening. At each scheduled visit, subjects undergo efficacy assessments for clinical worsening, exercise capacity (6MWD and Borg dyspnea score), WHO functional class (FC), and plasma N-Terminal pro-brain natriuretic peptide (NT-proBNP). Subjects could participate in an optional hemodynamic sub-study (assessed by RHC). Safety assessments consist of adverse events (AEs), physical examinations, vital signs, 12-lead electrocardiograms (ECGs), and clinical laboratory parameters. Patients who complete all required assessments are eligible to enter a long-term, open-label, extension study (TDE-PH-311).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary arterial hypertension (PAH)
  • Pulmonary hypertension (PH)
  • Clinical Worsening
  • Freedom
  • Freedom-EV
  • Treprostinil
  • UT-15C
  • 6 Minute walk test
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Subject Inclusion Criteria:

  1. Voluntarily gave to participate in the study.
  2. Are 18 to 75 years of age (inclusive) at Screening.
  3. Women of must practice abstinence from intercourse when in line with their preferred and usual lifestyle, or use 2 different forms of highly effective for the duration of the study, and for at least 30 days after discontinuing study medication. A negative urine pregnancy test is required at Screening and Baseline prior to initiating study medication.
  4. Male subjects must consent to use a condom during intercourse for the duration of the study, and for at least 48 hours after discontinuing study medication.
  5. Have a diagnosis of symptomatic idiopathic or heritable PAH, PAH associated with connective tissue disease (CTD), PAH associated with infection, PAH associated with repaired congenital systemic-to-pulmonary shunt, or PAH associated with appetite suppressant or toxin use.
  6. If known to be positive for HIV infection, have a of at least 200 cells/mm\^3 assessed at Screening and are receiving current standard of care anti retroviral or other effective medication for the treatment of HIV infection.
  7. Have a baseline 6MWD greater than or equal to 150 m in the absence of a concurrent injury, illness, or other confounding factor including, but not limited to, use of an aid for ambulation or connection to a nonportable machine, that would have prevented the accurate assessment of the subject's exercise capacity.
  8. Are optimally treated with conventional pulmonary hypertension therapy with no additions, discontinuations, or dose changes for a minimum of 10 days prior to randomization. The exceptions are the discontinuation or dose changes of anticoagulants and/or dose change of diuretics.
  9. Are receiving a PAH-approved oral monotherapy at a minimum dose that complies with the approved prescribing information for the product for at least 30 days prior to randomization and are receiving a stable dose for at least 10 days prior to randomization.
  10. Have had previously undergone a cardiac catheterization within 3 years prior to the start of Screening or during the Screening Period, and the most recent assessment documented a pulmonary artery pressure mean of at least 25 mmHg, a pulmonary capillary wedge pressure (PCWP) (or in the event a PCWP could not be reliably obtained, a left ventricular end diastolic pressure [LVEDP]) less than or equal to 15 mmHg, and absence of unrepaired congenital heart disease (other than patent foramen ovale). If a reliable PCWP or LVEDP are unable to be obtained during cardiac catheterization, subjects with clinically normal left heart function and absence of mitral valve disease on echocardiography are eligible for enrollment.
  11. Undergo echocardiography with evidence of clinically normal systolic and diastolic left ventricular function and absence of any clinically significant left sided heart disease (eg, mitral valve disease). Subjects with clinically insignificant left ventricular diastolic dysfunction due to the effects of right ventricular overload (ie, right ventricular hypertrophy and/or dilatation) are eligible.
  12. Have a previous ventilation perfusion lung scan, high-resolution computerized tomography scan of the chest, and/or pulmonary angiography that are consistent with the diagnosis of PAH.
  13. Have pulmonary function tests conducted within 6 months before Screening or during the Screening Period to confirm the following:

    1. Total lung capacity is at least 60%
    2. Forced expiratory volume at 1 second is at least 50%
  14. In the opinion of the Principal Investigator, is able to communicate effectively with study personnel and is considered reliable, willing, and likely to cooperate with protocol requirements, including attending all study visits.

Subject Exclusion Criteria:

  1. Is pregnant or lactating.
  2. Have previously received oral treprostinil.
  3. Have received a PGI2 (except if used during acute vasoreactivity testing) within 30 days prior to randomization or have previous intolerance or significant lack of efficacy to any PGI2 or PGI2 analogue that resulted in discontinuation or inability to titrate that therapy effectively.
  4. Have any background conventional therapies for PAH added, removed, or dose-adjusted within 10 days prior to randomization. The exceptions are removal or dose adjustments of anticoagulants and/or dose adjustments of diuretics.
  5. Receive their first dose of a PAH-approved oral monotherapy less than 30 days prior to randomization, or have their PAH-approved oral monotherapy dose changed within 10 days prior to randomization, or the subject discontinues any PAH approved therapy within 30 days prior to Screening, or the subject has previously received 2 PAH approved oral therapies at the same time (specifically, a PDE5-I, an ERA, or a sGC stimulator) concomitantly for more than 90 days cumulatively.
  6. Have any disease associated with PAH other than CTD, HIV infection, repaired (for at least 1 year) congenital systemic-to-pulmonary shunt, PAH associated with appetite suppressant/toxin use, or have an atrial septostomy.
  7. Have a current diagnosis of uncontrolled sleep apnea as defined by their physician.
  8. Have a history of ischemic heart disease, including a previous myocardial infarction or symptomatic coronary artery disease within 6 months prior to Screening or a history of left-sided myocardial disease as evidenced by a mean PCWP (or a LVEDP) greater than 15 mmHg or less than 40% as assessed by either multigated angiogram, angiography, or echocardiography.
  9. Have uncontrolled systemic hypertension as evidenced by systolic blood pressure (BP) greater than 160 mmHg or diastolic BP greater than 100 mmHg.
  10. Have or aspartate aminotransferase levels at least 3 times greater than the , clinically significant liver disease/dysfunction, or known Class C hepatic disease at Screening.
  11. Have any other disease or condition that would interfere with the interpretation of study assessments.
  12. Have a musculoskeletal disorder, is using a device to assist walking, or any disease that is likely to limit ambulation, or is connected to a machine that is nonportable.
  13. Have an unstable psychiatric condition or is mentally incapable of understanding the objectives, nature, or consequences of the study, or has any condition which in the Investigator's opinion would constitute an unacceptable risk to the subject's safety.
  14. Is receiving an drug, have an investigational device in place, or have participated in an investigational drug or device study within 30 days prior to Screening.
  15. Have chronic renal insufficiency as defined by either a Screening creatinine value greater than 2.5 mg/dL or the requirement for dialysis.
  16. Does not have 3 or more of the following left ventricular disease/dysfunction risk factors:

    1. at least 30 kg/m\^2
    2. History of essential hypertension
    3. Diabetes mellitus (any type)
    4. Historical evidence of significant coronary artery disease established by any 1 of the following: history of myocardial infarction, percutaneous coronary intervention, or angiographic evidence of coronary artery disease; positive stress test with imaging; previous coronary artery bypass graft; or stable angina.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
690 participants (actual)

Study arms

  • Experimental
    UT-15C

    Treprostinil diolamine extended-release tablets (oral) 0.125 to 12 mg TID

    Drug: Treprostinil Diolamine

  • Placebo comparator
    Placebo

    Matching placebo tablets (oral)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time to First Clinical Worsening Event

    Clinical worsening was assessed continuously from randomization until the subject's last study visit. Clinical worsening events were defined as death (all causes), hospitalizations due to worsening pulmonary arterial hypertension (PAH), initiation of an inhaled or infused prostacyclin (PGI2) for the treatment of worsening PAH, disease progression, or unsatisfactory long-term clinical response. All clinical worsening events reported by the study sites were reviewed by the Sponsor Medical Monitors. Once a clinical worsening event occurred, it was entered in the eCRF and a narrative was submitted for review by the Sponsor's Medical Monitor within 48 hours after the event became known to the Investigator or designee. Subsequently, the narratives for subjects with the reported clinical worsening events were sent to an independent adjudication committee. The independent adjudication committee reviewed and adjudicated all clinical worsening events throughout the study.

    Time frame: From randomization to approximately 4 years

Secondary outcomes

  1. Change in 6-Minute Walk Distance

    The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living. A baseline 6MWT was performed prior to initiation of study drug on the day of randomization. 6MWTs were conducted at Weeks 4, 8, 12, 24, and every 12 weeks thereafter. The change between Baseline and Week 24 is reported.

    Time frame: From Baseline to Week 24

  2. Change in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24

    Plasma NT-proBNP concentration is a useful biomarker for the severity of PAH as it is associated with changes in right heart morphology and function. NT-proBNP sample collection occurred at Baseline (prior to starting study drug), Week 12, Week 24, the first Continued Visit, and every other Continued Visit thereafter (ie, Continued Visits 3, 5, 7, etc). NT-proBNP was also assessed at the Study Drug Termination Visit. The change between Baseline and Week 24 is reported.

    Time frame: From Baseline to Week 24

  3. Change in World Health Organization Functional Class (WHO FC) From Baseline to Week 48

    The WHO FC for PAH was assessed at Baseline prior to starting study drug, at all subsequent scheduled study visits, and every time the 6MWT was performed for purposes of assessing clinical worsening status.

    Time frame: Baseline to Week 48

07

Results

Posted Feb 13, 2020

Participant flow

Participant flow — Overall Study
MilestoneUT-15CPlacebo
Started346344
Clinical worsening event91133
Early discontinuation from treatment10756
Completed148155
Not completed198189

Outcome measures

PrimaryTime to First Clinical Worsening Event

Clinical worsening was assessed continuously from randomization until the subject's last study visit. Clinical worsening events were defined as death (all causes), hospitalizations due to worsening pulmonary arterial hypertension (PAH), initiation of an inhaled or infused prostacyclin (PGI2) for the treatment of worsening PAH, disease progression, or unsatisfactory long-term clinical response. All clinical worsening events reported by the study sites were reviewed by the Sponsor Medical Monitors. Once a clinical worsening event occurred, it was entered in the eCRF and a narrative was submitted for review by the Sponsor's Medical Monitor within 48 hours after the event became known to the Investigator or designee. Subsequently, the narratives for subjects with the reported clinical worsening events were sent to an independent adjudication committee. The independent adjudication committee reviewed and adjudicated all clinical worsening events throughout the study.

Time frame:
From randomization to approximately 4 years
Reported as:
Mean · weeks
Time to First Clinical Worsening Event
weeksUT-15CPlacebo
Time to First Clinical Worsening Event60.58 ± 42.9349.31 ± 46.28
Statistical analysis
  • UT-15C vs Placebo · Cox proportion-hazard model · p = 0.0275 · Hazard ratio (hr): 0.74 · 95% CI 0.56 to 0.97
  • UT-15C vs Placebo · Log Rank · p = 0.0391
SecondaryChange in 6-Minute Walk Distance

The intent of the 6-Minute Walk Test (6MWT) is to evaluate exercise capacity associated with carrying out activities of daily living. A baseline 6MWT was performed prior to initiation of study drug on the day of randomization. 6MWTs were conducted at Weeks 4, 8, 12, 24, and every 12 weeks thereafter. The change between Baseline and Week 24 is reported.

Time frame:
From Baseline to Week 24
Reported as:
Mean · meters
Change in 6-Minute Walk Distance
metersUT-15CPlacebo
Baseline392.9 ± 92.5398.5 ± 100.00
Week 24395.4 ± 120.0372.3 ± 163.0
Statistical analysis
  • UT-15C vs Placebo · ANCOVA · p = 0.0913 · Hodges lehmann estimate location shift: 7.0 · 95% CI 0 to 16.0
SecondaryChange in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24

Plasma NT-proBNP concentration is a useful biomarker for the severity of PAH as it is associated with changes in right heart morphology and function. NT-proBNP sample collection occurred at Baseline (prior to starting study drug), Week 12, Week 24, the first Continued Visit, and every other Continued Visit thereafter (ie, Continued Visits 3, 5, 7, etc). NT-proBNP was also assessed at the Study Drug Termination Visit. The change between Baseline and Week 24 is reported.

Time frame:
From Baseline to Week 24
Reported as:
Least squares mean · Ratio to baseline
Change in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 24
Ratio to baselineUT-15CPlacebo
Change in Plasma N-Terminal Pro-brain Natriuretic Peptide (NT-proBNP) From Baseline to Week 240.7859 ± 1.054701.1230 ± 1.05439
Statistical analysis
  • UT-15C vs Placebo · ANCOVA · p = <0.0001
SecondaryChange in World Health Organization Functional Class (WHO FC) From Baseline to Week 48

The WHO FC for PAH was assessed at Baseline prior to starting study drug, at all subsequent scheduled study visits, and every time the 6MWT was performed for purposes of assessing clinical worsening status.

Time frame:
Baseline to Week 48
Reported as:
Count of participants · Participants
Change in World Health Organization Functional Class (WHO FC) From Baseline to Week 48
ParticipantsUT-15CPlacebo
Improved4638
No change203170
Deteriorated66103
Statistical analysis
  • UT-15C vs Placebo · Fisher Exact · p = 0.0028

Adverse events

Collected over The study lasted 6 years; however, subjects remained in the study for various durations. The longest subject duration in the study was 5.1 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
UT-15C17/346 (4.9%)116/346 (33.5%)342/346 (98.8%)
Placebo18/344 (5.2%)110/344 (32%)328/344 (95.3%)
Most frequent serious events
Showing 10 of 187
Most frequent serious events
EventUT-15CPlacebo
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders26/34636/344
Right ventricular failureCardiac disorders17/34612/344
PneumoniaInfections and infestations10/34610/344
DyspnoeaRespiratory, thoracic and mediastinal disorders7/3468/344
Chest painGeneral disorders2/3465/344
Cardiac failureCardiac disorders5/3463/344
GastroenteritisInfections and infestations5/3460/344
Upper respiratory tract infectionInfections and infestations5/3463/344
HypotensionVascular disorders2/3464/344
SyncopeNervous system disorders2/3464/344
Most frequent other events
Showing 10 of 47
Most frequent other events
EventUT-15CPlacebo
HeadacheNervous system disorders259/346120/344
DiarrhoeaGastrointestinal disorders240/34698/344
FlushingVascular disorders154/34627/344
NauseaGastrointestinal disorders139/34678/344
VomitingGastrointestinal disorders123/34635/344
Upper respiratory tract infectionInfections and infestations73/34682/344
Oedema peripheralGeneral disorders46/34681/344
DizzinessNervous system disorders81/34675/344
DyspnoeaRespiratory, thoracic and mediastinal disorders56/34677/344
Pulmonary hypertensionRespiratory, thoracic and mediastinal disorders38/34664/344

Baseline characteristics

The Intent-to-Treat (ITT) Population was defined as all subjects randomized into the study who received at least 1 dose of study drug. The Safety Population was defined as all subjects in the study that received study drug. ITT subjects with major protocol deviations were excluded from the Per-Protocol population.

Age, Categorical
Age, Categorical(Participants)UT-15CPlaceboTotal
<=18 years000
Between 18 and 65 years292294586
>=65 years5450104
Age, Continuous
Age, Continuous(years)UT-15CPlaceboTotal
Mean45.6 ± 15.744.8 ± 15.445.2 ± 15.5
Sex: Female, Male
Sex: Female, Male(Participants)UT-15CPlaceboTotal
Female275269544
Male7175146
Race (NIH/OMB)
Race (NIH/OMB)(Participants)UT-15CPlaceboTotal
American Indian or Alaska Native000
Asian150156306
Native Hawaiian or Other Pacific Islander000
Black or African American81321
White187173360
More than one race000
Unknown or Not Reported123
Region of Enrollment
Region of Enrollment(Participants)UT-15CPlaceboTotal
North America395493
Southeast Asia162160322
Europe554499
South America9086176
Time since Diagnosis
Time since Diagnosis(years)UT-15CPlaceboTotal
Mean1.34 ± 2.501.37 ± 2.581.35 ± 2.54
6MWD at Baseline
6MWD at Baseline(meters)UT-15CPlaceboTotal
Mean392.9 ± 92.5398.5 ± 100.0395.7 ± 96.3
Etiology of PAH
Etiology of PAH(Participants)UT-15CPlaceboTotal
Idiopathic or Heritable PAH219216435
Collagen Vascular Disease9484178
HIV Infection279
Congenital Heart Defect202747
Other111021

1 further baseline measures are reported on the registry.

08

Study locations

155 sites
  • Arizona Pulmonary Specialists, Ltd.
    Phoenix, Arizona 85012, United States
  • University of Arizona
    Tucson, Arizona 85724, United States
  • University of California, San Francisco-Fresno
    Fresno, California 93721, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90211, United States
  • University of California-Davis Medical Group, Advanced Lung Disease/Transplant Program
    Sacramento, California 95817, United States
  • David Geffen School of Medicine
    Torrance, California 90502, United States
  • University of Colorado Hospital
    Aurora, Colorado 80045, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • University of Florida College of Medicine Jacksonville- Division of Pulmonary & Critical Medicine
    Jacksonville, Florida 32209, United States
  • University of Florida College of Medicine Jacksonville
    Jacksonville, Florida 32209, United States
  • University of Florida College of Medicine, Jacksonville
    Jacksonville, Florida 32209, United States
  • Cleveland Clinic Florida
    Weston, Florida 33331, United States
  • Emory University Hospital
    Atlanta, Georgia 30322, United States
  • Augusta University
    Augusta, Georgia 30912, United States
  • Piedmont - Georgia Lung Associates
    Austell, Georgia 30106, United States
  • HeartCare Midwest
    Peoria, Illinois 61614, United States
  • Indiana University Hospital
    Carmel, Indiana 46032, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 55242, United States
  • Kentuckiana Pulmonary Associates
    Louisville, Kentucky 40202, United States
  • University of Maryland
    Baltimore, Maryland 21201, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Henry Ford Health System
    Detroit, Michigan 48202, United States
  • Beaumont Health
    Troy, Michigan 48085, United States
  • Nebraska Medical Center
    Omaha, Nebraska 68198-5990, United States
  • Newark Beth Israel Medical Center
    Newark, New Jersey 07112, United States
  • University of Rochester
    Rochester, New York 14642, United States
  • Asheville Cardiology Associates
    Asheville, North Carolina 28803, United States
  • University of Cincinnati
    Cincinnati, Ohio 45267-0564, United States
  • University Hospital
    Cleveland, Ohio 44106, United States
  • The Ohio State University
    Columbus, Ohio 43321, United States
  • Oregon Health and Science University
    Portland, Oregon 97201-3098, United States
  • Legacy Research Institute
    Portland, Oregon 97210, United States
  • Perelman Center for Advanced Medicine; University of Pennsylvania
    Philadelphia, Pennsylvania 19104, United States
  • University of Pittsburgh Medical Center - Presbyterian Cardiovascular Institute
    Pittsburgh, Pennsylvania 15213, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • The University of Texas Health Science Center at Houston
    Houston, Texas 77030, United States
  • Sentara Cardiovascular Research Institute
    Norfolk, Virginia 23507, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298, United States
  • Aurora Saint Luke's Medical Center
    Milwaukee, Wisconsin 53215, United States
  • Sanatorio San José
    Caba, Buenos Aires C1425DUH, Argentina
  • Hospital Italiano de Buenos Aires
    Ciudad Autónoma de Buenos Aires, Distrito Federal C1181ACH, Argentina
  • Hospital Italiano Garibaldi
    Rosario, Santa Fe S2001OAD, Argentina
  • Sanatorio de la Trinidad Mitre
    Buenos Aires, Argentina
  • Hospital Dr. José María Cullen
    Santa Fe, S3000EOY, Argentina
  • Royal Prince Alfred Hospital
    Camperdown, New South Wales 2050, Australia
  • Nepean Hospital
    Kingswood, New South Wales 2751, Australia
  • Saint Vincents Hospital
    Sydney, New South Wales 2010, Australia
  • Macquarie University
    Sydney, New South Wales 2109, Australia
  • Prince Charles Hospital
    Chermside, Queensland 4032, Australia
  • Royal Hobart Hospital
    Hobart, Tasmania 7000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
  • Royal Melbourne Hospital
    Parkville, Victoria 3052, Australia
  • Krankenhaus Elisabethinen Linz
    Linz, Upper Austria 4020, Austria
  • Medizinische Universität Wien
    Wien, 1090, Austria
  • Hospital das Clinicas da Universidade Federal de Goias
    Goiania, Goias 74605-050, Brazil
  • Hospital das Clínicas da Universidade Federal de Minas Gerais
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Hospital Madre Teresa
    Belo Horizonte, Minas Gerais 30380-090, Brazil
  • Complexo Hospitalar Santa Casa de Porto Alegre
    Porto Alegre, RIO Grande DO SUL 90020-090, Brazil
  • Hospital das Clínicas da Faculdade de Medicina de Botucatu- UNESP
    Botucatu, SAO Paulo 18618-970, Brazil
  • Hospital da Clínicas da Faculdade de Medicina da Universidade de São Paulo
    São Paulo, SAO Paulo 05403-000, Brazil
  • Escola Paulista de Medicina, Universidade Federal de São Paulo
    São Paulo, SAO Paulo, Brazil
  • Hospital Alemão Oswaldo Cruz
    São Paulo, 01323-020, Brazil
  • Respiratory Research Foundation
    Calgary, Alberta T1Y 6J4, Canada
  • University of Alberta Hospital
    Edmonton, Alberta T6G 2B7, Canada
  • Vancouver Coastal Health
    Vancouver, British Columbia V5Z 1M9, Canada
  • Lawson Health Research Institute
    London, Ontario N6A 5A5, Canada
  • Centro de Investigaciones TASOL
    Santiago, Region Metropolitana 7500710, Chile
  • Clínica Tabancura
    Vitacura, Santiago 7650018, Chile
  • Beijing Chao-Yang Hospital
    Beijing, Beijing 100020, China
  • Guangdong General Hospital
    Guangzhou, Guangdong 510080, China
  • Wuhan Asia Heart Hospital
    Wuhan, Hubei 430022, China
  • Xiangya Hospital
    Changsha, Hunan 410008, China
  • The First Affiliated Hospital of Nanjing Medical University
    Nanjing, Jiangsu 210029, China
  • The Second Affiliated Hospital of Nanchang Medical University
    Nanchang, Jiangxi 330006, China
  • Zhongshan Hospital Fudan University
    Shanghai, Shanghai 200032, China
  • Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200120, China
  • West China Hospital
    Chengdu, Sichuan 610047, China
  • Peking Union Medical College Hospital
    Beijing, 100005, China
  • Beijing Shijitan Hospital
    Beijing, 100038, China
  • Chinese PLA General Hospital
    Beijing, 100853, China
  • The Affiliated Hospital of Qingdao University
    Qingdao, 26603, China
  • Renji Hospital of Shanghai Jiaotong University
    Shanghai, 200001, China
  • Shanghai Pulmonary Hospital of Tongji University
    Shanghai, 200433, China
  • Shenyang General Hospital of Shenyang Military Command
    Shenyang, 110015, China
  • Aarhus Universitetshospital, Skejby
    Aarhus, 8200, Denmark
  • Rigshospitalet-Copenhagen University Hospital
    Copenhagen, 2100, Denmark
  • Hopital Haut-Leveque, CHU Bordeaux
    Pessac, Aquitaine 33064, France
  • Hopital Jean Minjoz Centre Hospitalier Universitaire Besancon
    Besancon, Franche-comte 25030, France
  • CHU de Montpellier
    Montpellier Cedex 5, Languedoc-roussillon 34295, France
  • Hopital Brabois
    Vandoeuvre-Les-Nancy, Limousin, Lorraine 54500, France
  • Centre Hospitalier Régional Universitaire de Lille - Hôpital Claude Huriez
    Lille, NORD Pas-de-calais 59037, France
  • Centre Hospitalier Universitaire Hopital Nord
    Marseille, Provence Alpes COTE D'azur 13015, France
  • Thoraxklinik am Universitätsklinikum Heidelberg
    Heidelberg, Baden-wuerttemberg 69126, Germany
  • Ludwig-Maximilians-Universitat Munchen
    Munchen, Bayern 81377, Germany
  • Universitätsklinikum Regensburg
    Regensburg, Bayern 93053, Germany
  • Missionsarztliche Klinik Wurzburg gGmbH
    Wurzburg, Bayern 97074, Germany
  • Universitätsmedizin Greifswald
    Greifswald, Mecklenburg-vorpommern 17475, Germany
  • Bergmannsheil Berufsgenossenschaftliche Universitätsklinik GmbH
    Bochum, Nordrhein-westfalen 44789, Germany
  • Herzzentrum Duisburg
    Duisburg, Nordrhein-westfalen 47137, Germany

Showing the first 100 of 155 sites across 23 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grunig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. PubMed 31765604 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2012 to primary completion in Jun 2018, 71 months.

Results were first posted in Feb 2020, 1 year 7 months after primary completion. A results delay was requested in Apr 2019.

Of 43 industry-sponsored phase 3 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 31 and three quarters within 83. This study's 71 months is above that.

Counting every sponsor, half of 49 studies reached it within 50 months; a quarter within 31 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2012
First posted
Mar 22, 2012
StartActual
Jun 26, 2012
Primary completionActual
Jun 24, 2018
CompletionActual
Jun 24, 2018
Results delay requested
Apr 15, 2019
Results first posted
Feb 13, 2020
Last update
Feb 13, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01560624
Responsible party
Sponsor
First posted
Mar 22, 2012
Start date
Jun 26, 2012
Primary completion
Jun 24, 2018
Completion
Jun 24, 2018
Results posted
Feb 13, 2020
Last update
Feb 13, 2020

Study contacts

James White, MD, PhD
principal investigator · Mary M. Parkes Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion